skip to main content
Idioma:

Differences in human papillomavirus type distribution in high‐grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe

Tjalma, Wiebren A. ; Fiander, Alison ; Reich, Olaf ; Powell, Ned ; Nowakowski, Andrzej M. ; Kirschner, Benny ; Koiss, Robert ; O'Leary, John ; Joura, Elmar A. ; Rosenlund, Mats ; Colau, Brigitte ; Schledermann, Doris ; Kukk, Kersti ; Damaskou, Vasileia ; Repanti, Maria ; Vladareanu, Radu ; Kolomiets, Larisa ; Savicheva, Alevtina ; Shipitsyna, Elena ; Ordi, Jaume ; Molijn, Anco ; Quint, Wim ; Raillard, Alice ; Rosillon, Dominique ; De Souza, Sabrina Collas ; Jenkins, David ; Holl, Katsiaryna

International journal of cancer, 2013-02, Vol.132 (4), p.854-867 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
  • Título:
    Differences in human papillomavirus type distribution in high‐grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe
  • Autor: Tjalma, Wiebren A. ; Fiander, Alison ; Reich, Olaf ; Powell, Ned ; Nowakowski, Andrzej M. ; Kirschner, Benny ; Koiss, Robert ; O'Leary, John ; Joura, Elmar A. ; Rosenlund, Mats ; Colau, Brigitte ; Schledermann, Doris ; Kukk, Kersti ; Damaskou, Vasileia ; Repanti, Maria ; Vladareanu, Radu ; Kolomiets, Larisa ; Savicheva, Alevtina ; Shipitsyna, Elena ; Ordi, Jaume ; Molijn, Anco ; Quint, Wim ; Raillard, Alice ; Rosillon, Dominique ; De Souza, Sabrina Collas ; Jenkins, David ; Holl, Katsiaryna
  • Assuntos: Adenocarcinoma ; Adolescent ; Adult ; Age ; Aged ; Aged, 80 and over ; Alphapapillomavirus - classification ; Alphapapillomavirus - genetics ; Alphapapillomavirus - isolation & purification ; Cancer ; Cervical cancer ; cervical intraepithelial neoplasia ; Cervical Intraepithelial Neoplasia - pathology ; Cervical Intraepithelial Neoplasia - virology ; Cervix Uteri - pathology ; Cervix Uteri - virology ; CIN ; Cross-Sectional Studies ; DNA, Viral - analysis ; Europe - epidemiology ; Female ; HPV ; Human papillomavirus ; Humans ; Medicin och hälsovetenskap ; Middle Aged ; Neoplasm Grading ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - virology ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - virology ; Young Adult
  • É parte de: International journal of cancer, 2013-02, Vol.132 (4), p.854-867
  • Notas: W.A.T. and A.F. contributed equally to this work
    Conflicts of Interest: W.A. Tjalma has received support for travel to meetings for the study or other purposes from GSK, Merck and Sanofi Pasteur. A. Fiander has been on advisory boards for both GSK and Sanofi Pasteur MSD and received research grant funding and support to attend HPV‐related conferences from both companies. N. Powell's laboratory has received funding from GSK, including for the work in support of this study; he has received honoraria from GSK and Sanofi Pasteur to speak/advise on HPV and has also received support for travel to study‐related meetings. A.M. Nowakowski and his institution have been paid by GSK for participation in the study, and he has received support for travel to study‐related meetings; he has also been paid by GSK and MSD for lectures. B. Kirschner has received support from GSK for travel and is a paid consultant to GSK's Advisory Board on vaccine‐related issues. J. O'Leary, V. Damaskou, M. Repanti and their institutions received funding from GSK to complete the work disclosed in this publication. E.A. Joura and his institution have received grants from GSK and Merck for HPV vaccine studies; he is also a paid member of the board of Merck (HPV vaccines), has received travel expenses from Merck, Sanofi Pasteur MSD and GSK and has also been paid by GSK, Merck and Sanofi Pasteur MSD for lectures. M. Rosenlund was employed by GSK Biologicals at the time of study; B. Colau, K. Holl and D. Rosillon are employed by GSK Biologicals; B. Colau and M. Rosenlund also have stock or stock options in GSK Biologicals. D. Schledermann has received support from GSK for congress registration and travel. A. Savicheva and E. Shipitsyna have received consulting fees or honoraria for their participation in the study and travel expenses and have previously participated in a HPV vaccine trial for GSK. The employer of A. Molijn and W. Quint, DDL Diagnostic Laboratories, has received support from GSK for travel to meetings for the study or other purposes, fees for participation in review activities such as data monitoring boards, statistical analysis and end‐point committees and also grants and fees for consultancy outside the submitted work. The employer of S. Collas De Souza and A. Raillard, 4Clinics, has received consulting fees from GSK for statistical analysis. D. Jenkins was, at the time of this study, initially an employee and then consultant in HPV to GSK Biologicals. O. Reich, R. Koiss, K. Kukk, R. Vladareanu, L. Kolomiets and J. Ordi declare no conflicts of interest. Role of the funding source: The costs related to the collection of tissue and the analysis of data from both studies, together with the development of this article, were funded and coordinated by GlaxoSmithKline Biologicals.
    Fax: +32‐3‐828‐39‐85
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    ObjectType-Article-2
    ObjectType-Feature-1
  • Descrição: Knowledge of differences in human papillomavirus (HPV)‐type prevalence between high‐grade cervical intraepithelial neoplasia (HG‐CIN) and invasive cervical cancer (ICC) is crucial for understanding the natural history of HPV‐infected cervical lesions and the potential impact of HPV vaccination on cervical cancer prevention. More than 6,000 women diagnosed with HG‐CIN or ICC from 17 European countries were enrolled in two parallel cross‐sectional studies (108288/108290). Centralised histopathology review and standardised HPV‐DNA typing were applied to formalin‐fixed paraffin‐embedded cervical specimens dated 2001–2008. The pooled prevalence of individual HPV types was estimated using meta‐analytic methods. A total of 3,103 women were diagnosed with HG‐CIN and a total of 3,162 with ICC (median ages: 34 and 49 years, respectively), of which 98.5 and 91.8% were HPV‐positive, respectively. The most common HPV types in women with HG‐CIN were HPV16/33/31 (59.9/10.5/9.0%) and in ICC were HPV16/18/45 (63.3/15.2/5.3%). In squamous cell carcinomas, HPV16/18/33 were most frequent (66.2/10.8/5.3%), and in adenocarcinomas, HPV16/18/45 (54.2/40.4/8.3%). The prevalence of HPV16/18/45 was 1.1/3.5/2.5 times higher in ICC than in HG‐CIN. The difference in age at diagnosis between CIN3 and squamous cervical cancer for HPV18 (9 years) was significantly less compared to HPV31/33/‘other’ (23/20/17 years), and for HPV45 (1 year) than HPV16/31/33/‘other’ (15/23/20/17 years). In Europe, HPV16 predominates in both HG‐CIN and ICC, whereas HPV18/45 are associated with a low median age of ICC. HPV18/45 are more frequent in ICC than HG‐CIN and associated with a high median age of HG‐CIN, with a narrow age interval between HG‐CIN and ICC detection. These findings support the need for primary prevention of HPV16/18/45‐related cervical lesions.
  • Editor: Hoboken: Wiley Subscription Services, Inc., A Wiley Company
  • Idioma: Inglês;Russo
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.